Capsomere, recombinant human adeno-associated virus AAV3B viral capsid protein VP1-VP2-VP3 complex (1:2:7), hexacontamer, complex with DNA (recombinant replication-defective adeno-associated virus serotype 3B vector VTX-801 liver-specific human ?-1 antitrypsin promoter plus human 57-486-copper transporter ATP7B codon-optimized gene plus rabbit ?-globin polyadenylation signal plus adeno-associated virus 2 inverted terminal repeat flanks) (1:1)
Wilson's Disease
Vivet Therapeutics SASgene_therapyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
11 Active assets in the Wilson's Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ZINC ACETATE Nobelpharma | Phase 4 | BBB |
Teta 4Hcl Orphalan | Phase 3 | BBB |
ZINC D-GLUCONATE (1:2) Jun Li | Phase 4 | BBB |
Trientine Excelsior | Phase 3 | BB |
Penicillamine Orphalan | Phase 3 | BB |
View all 21 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →